Kosan BioSciences -- KOSN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Kosan BioSciences -- KOSN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: mopgcw who wrote (685)	5/4/2006 11:21:17 AM
From: keokalani'nui	Read Replies (1) of 933

CAMBRIDGE, Mass. & SAN DIEGO--(BUSINESS WIRE)--May 3, 2006--Biogen Idec (NASDAQ: BIIB - News) and Conforma Therapeutics Corporation, a privately held biopharmaceutical company focused on the design and development of novel drugs for the treatment of cancer, today announced that they have signed a definitive merger agreement for the acquisition of Conforma by Biogen Idec. Conforma, founded in 1999, is focused on the discovery and development of drugs that inhibit heat shock protein 90 (HSP90) molecules, which are involved in protecting and supporting the growth of cancer cells across a range of tumor types, and which also play a role in tumor resistance to a number of leading cancer therapies. The company has advanced two compounds into Phase I clinical trials: CNF1010, a proprietary form of the geldanamycin derivative 17-AAG; and CNF2024, a totally synthetic, orally bioavailable HSP90 inhibitor.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next